The generic drug manufacturers also sought to have the patent declared invalid on the grounds that the NIH researchers who did the human cell screening were not identified in the patent as co-inventors.
Generic pharmaceutical companies sought to have their patent declared invalid, arguing that the NIH researchers responsible for conducting human cell screenings were not credited as co-inventors in the patent application, which had implications for the ownership and control of the intellectual property.